Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals | Zendy

Eugènia Negredo | Zendy; Vicente Estrada | Zendy; Peré Domingo | Zendy; María del Mar Gutiérrez | Zendy; Gràcia Mateo | Zendy; Jordi Puig | Zendy; Anna Bonjoch | Zendy; Arelly Ornelas | Zendy; Patricia Echeverría | Zendy; Carla Estany | Zendy; Jessica Toro | Zendy; Bonaventura Clotet | Zendy

Open Access

Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals

Author(s) -

Eugènia Negredo,

Vicente Estrada,

Peré Domingo,

María del Mar Gutiérrez,

Gràcia Mateo,

Jordi Puig,

Anna Bonjoch,

Arelly Ornelas,

Patricia Echeverría,

Carla Estany,

Jessica Toro,

Bonaventura Clotet

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw504

Subject(s) - dolutegravir , medicine , ritonavir , abacavir , osteoporosis , regimen , osteopenia , lamivudine , gastroenterology , bone mineral , randomized controlled trial , urology , viral load , human immunodeficiency virus (hiv) , virology , virus , antiretroviral therapy , hepatitis b virus

Switching from PIs to dolutegravir in virologically suppressed HIV-infected individuals has not been assessed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research